NEW YORK, NY / ACCESSWIRE / February 7, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

YMAB Shareholders Click Here: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=36321&wire=1
ALIZY Shareholders Click Here: https://www.zlk.com/pslra-1/allianz-se-class-action-submission-form?prid=36321&wire=1
SQ Shareholders Click Here: https://www.zlk.com/pslra-1/block-class-action-lawsuit-submission-form?prid=36321&wire=1

* ADDITIONAL INFORMATION BELOW *

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
Lead Plaintiff Deadline: March 20, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=36321&wire=1

According to the filed complaint, (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ('FDA') willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.

Allianz SE (OTCMKT:ALIZY)

ALIZY Lawsuit on behalf of: investors who purchased March 9, 2018 - May 17, 2022
Lead Plaintiff Deadline : April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/allianz-se-class-action-submission-form?prid=36321&wire=1

According to the filed complaint, during the class period, Allianz SE made materially false and/or misleading statements and/or failed to disclose that: (1) Allianz did not have effective internal controls; (2) Allianz's subsidiary was involved in substantial fraudulent activity; (3) as a result, Allianz was at an increased risk of regulatory scrutiny; (4) as a result, Allianz was at an increased risk of substantial losses and financial costs; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times.

Block, Inc. (NYSE:SQ)

This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Block securities during the period November 4, 2021 and April 4, 2022, including all former shareholders of Afterpay securities who acquired unregistered Block, Inc. Class A common stock (and/or corresponding SQ CHESS Depository Interests) in direct exchange for Afterpay shares pursuant to Block's January 31, 2022 acquisition and stock-for-stock merger with Afterpay.
Lead Plaintiff Deadline: April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/block-class-action-lawsuit-submission-form?prid=36321&wire=1

According to the filed complaint, (1) defendants did not satisfy the mandatory conditions necessary to exempt them from registration under §3(a)(10) and permit the issuance and sale of unregistered Block Shares; (2) in violation of §§5(a) and (c) of the Securities Act, no registration statement has been filed with the U.S. Securities and Exchange Commission or been in effect with respect to these Block Shares issued, solicited, and sold by means of Block's January 31, 2022 acquisition and stock-for-stock merger with Afterpay (the 'Merger' or 'Acquisition'); (3) in order to push the Acquisition through, defendants failed to comply with §3(a)(10)'s mandatory preconditions in several respects; and (4) defendants' grossly negligent failures deprived the Supreme Court of New South Wales ('NSW Court') of critical information necessary for any genuine appraisal of the Merger's supposed 'fairness,' and furthermore deprived plaintiff and other Afterpay shareholders of their statutory right to appear and present to the NSW Court the host of serious concerns and material (yet undisclosed) information ahead of the Merger.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP